Nivolumab

In this article, we will discuss about Nivolumab (Dosage Overview). So, let’s get started.

Dosage

• Administer by intravenous infusion based upon recommended infusion rate for each indication.

Unresectable or metastatic melanoma
• 240 mg every 2 weeks or 480 mg every 4 weeks.
• 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks.

Adjuvant treatment of melanoma
• 240 mg every 2 weeks or 480 mg every 4 weeks.
• Metastatic non-small cell lung cancer
• 3 mg/kg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks.
• 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks and 2 cycles of platinum-doublet chemotherapy.
• 240 mg every 2 weeks or 480 mg every 4 weeks.
• Malignant pleural mesothelioma
• 360 mg every 3 weeks with ipilimumab 1 mg/kg every 6 weeks.

Advanced renal cell carcinoma
• 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4 weeks.
• 240 mg every 2 weeks or 480 mg every 4 weeks administered in combination with cabozantinib 40 mg once daily without food.
• 240 mg every 2 weeks or 480 mg every 4 weeks.

Classical Hodgkin lymphoma
• 240 mg every 2 weeks or 480 mg every 4 weeks.

Recurrent or metastatic squamous cell carcinoma of the head and neck
• 240 mg every 2 weeks or 480 mg every 4 weeks.

Locally advanced or metastatic urothelial carcinoma
• 240 mg every 2 weeks or 480 mg every 4 weeks.

Microsatellite instability-high (MSI-H) or mismatch repair deficient (DMMR) metastatic colorectal cancer
• Adult and pediatric patients ≥40 kg: 240 mg every 2 weeks or 480 mg every 4 weeks.
• Pediatric patients <40 kg: 3 mg/kg every 2 weeks.
• Adult and pediatrie patients ≥40 kg: 3 mg/kg followed by ipilimumab 1 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 my every 4 weeks

Hepatocellular carcinoma
• 240 mg every 2 weeks or 480 mg every 4 weeks.
• 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for 4 doses, then 240 mg, every 2 weeks or 480 mg every 4 weeks.

Esophageal squamous cell carcinoma
• 240 mg every 2 weeks or 480 mg every 4 weeks.

Adverse Reactions

Most common adverse reactions (incidence ≥20%) in patients were:
• As a single agent: fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, and vomiting.
• In combination with ipilimumab: fatigue, diarrhea, rash, pruritus, nausea, musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnea, upper respiratory tract infection, arthralgia, headache, hypothyroidism, decreased weight, and dizziness.
• In combination with ipilimumab and platinum-doublet chemotherapy:
fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite,
constipation, and pruritus.
• In combination with cabozantinib: diarrhea, fatigue, hepatotoxicity, palmar-plantar erythrodysaesthesia syndrome, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.